CRMO Pharmatech reposted this
The biopharma industry stands at a pivotal crossroads, with patent expirations threatening to cut $183.5 billion from annual sales by 2030. Major players like Amgen, Bristol Myers Squibb and Merck face a significant revenue cliff. But with $383.1 billion ready for M&A, the strategic scenario is set for a major shift. Companies like Johnson & Johnson and Novo Nordisk are in prime positions to leverage their resources for growth, while others must navigate this challenge with strategic acquisitions to safeguard their revenue streams. As the industry adapts, bold moves and smart deals will be key to thriving in this evolving environment. Read more: https://lnkd.in/dwT3bznj #Biopharma #PatentCliff #MergersAndAcquisitions #IndustryTrends #StrategicGrowth #pharmalinkage #pharmacy #pharmaceuticals #pharma #Biopharma #biopharmaceuticals #PharmaBusiness
